<DOC>
	<DOC>NCT00329238</DOC>
	<brief_summary>The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.</brief_summary>
	<brief_title>Secondary Prevention of Venous Thrombo Embolism (VTE).</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criteria: Inclusion_Criteria Acute symptomatic deep vein thrombosis (DVT) Pulmonary embolism (PE) 312 months prior to screening, which has been documented by objective testing Exclusion criteria: Exclusion_Criteria Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 312 months of treatment for the prior VTE. Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) &gt; 2x ULN Severe renal impairment (estimated creatinine clearance &lt;= 30 ml/min)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>